复宏汉霖的进击密码

药渡
Aug 10

近日,复宏汉霖发布了一条并不“起眼”的消息:公司自主研发和生产的抗PD-1单抗H药(斯鲁利单抗)完成首批面向印度市场的供货。看似低调的动作背后,是其国际化布局的厚积薄发:斯鲁利单抗已在近40个国家和地区获批,覆盖全球近半数人口;作为国内国际化最成功的Biotech之一,复宏汉霖已有四款自研产品登陆海外,仅2024年就递交25项全球上市注册申请、斩获17项批准,足迹遍布中欧美及印尼等新兴市场。这组...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10